Literature DB >> 17658446

Characterization of the anti-Leishmania effect induced by cisplatin, an anticancer drug.

J Tavares1, M Ouaissi, A Ouaissi, A Cordeiro-da-Silva.   

Abstract

The cis-diamminedichloroplatinum(II), known as cis-DDP or cisplatin is a widely used drug in cancer chemotherapy. Although a recent study has shown the anti-Leishmania activity of some cis-DDP derivatives, the cytotoxic properties were measured only on promastigotes, the insect vector form of the parasite. In this study the effect of cis-DDP on promastigotes and amastigotes, the vertebrate stage of the parasite is reported. The IC50, determined by flow cytometry, after 72 h of drug incubation was four times higher, 7.73+/-1.03 microM in the case of promastigotes compared to axenic amastigotes, 1.88+/-0.10 microM. In intracellular amastigotes the IC50, determined by counting the parasite index was 1.85+/-0.22 microM. By using flow cytometry, two patterns of cell cycle changes was observed: cis-DDP treated promastigotes and amastigotes accumulated in S phase and G2 phase, respectively. The cis-DDP response was also found to involve an "apoptosis-like" death of both promastigotes and amastigotes. However, DNA fragmentation was only detected in promastigote forms. In contrast mitochondrial transmembrane potential loss was observed for both stages of the parasite. Upon incubation of parasites with the drug an increase on GSH and GSSG levels and reactive oxygen species could be detected in the case of promastigote. Moreover, a slight increase of GSH level was detected on amastigote form. Taken together, these observations indicate that amastigotes are more sensitive to cis-DDP when compared to promastigotes. However, the signaling pathways leading to cell death could be different.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17658446     DOI: 10.1016/j.actatropica.2007.05.017

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  6 in total

1.  Library of Seleno-Compounds as Novel Agents against Leishmania Species.

Authors:  Álvaro Martín-Montes; Daniel Plano; Rubén Martín-Escolano; Verónica Alcolea; Marta Díaz; Silvia Pérez-Silanes; Socorro Espuelas; Esther Moreno; Clotilde Marín; Ramón Gutiérrez-Sánchez; Carmen Sanmartín; Manuel Sánchez-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.

Authors:  Tejinder Kaur; Prerna Makkar; Kulbir Randhawa; Sukhbir Kaur
Journal:  Parasitol Res       Date:  2012-09-09       Impact factor: 2.289

3.  Molecular Basis of the Leishmanicidal Activity of the Antidepressant Sertraline as a Drug Repurposing Candidate.

Authors:  Marta L Lima; María A Abengózar; Montserrat Nácher-Vázquez; María P Martínez-Alcázar; Coral Barbas; Andre G Tempone; Ángeles López-Gonzálvez; Luis Rivas
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

4.  Studies on the protective and immunomodulatory efficacy of Withania somnifera along with cisplatin against experimental visceral leishmaniasis.

Authors:  Heena Sachdeva; Rakesh Sehgal; Sukhbir Kaur
Journal:  Parasitol Res       Date:  2013-03-22       Impact factor: 2.289

5.  Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis.

Authors:  Meenakshi Sharma; Rakesh Sehgal; Sukhbir Kaur
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01

6.  The crystal structure of the Leishmania infantum Silent Information Regulator 2 related protein 1: Implications to protein function and drug design.

Authors:  Céline Ronin; David Mendes Costa; Joana Tavares; Joana Faria; Fabrice Ciesielski; Paola Ciapetti; Terry K Smith; Jane MacDougall; Anabela Cordeiro-da-Silva; Iain K Pemberton
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.